Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 14/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.48 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | PRNP | P04156 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31301500 | 0.86 | KMO (0.69) | KMO | |
| SCHEMBL28048792 | 0.83 | MEN1 (0.53) | KMOMAP4K4KDM4EMEN1PRNP | |
| SCHEMBL3183738 | 0.79 | MAPK8 (0.55) | KMOMAP4K4KDM4EMEN1KMT2A | |
| SCHEMBL3721991 | 0.76 | KMO (0.53) | KMOMAP4K4KIF11KMT2A | |
| SCHEMBL1758345 | 0.76 | MAP4K4 (0.54) | KMOMAP4K4KIF11DHODH | |
| SCHEMBL3454021 | 0.76 | KMO (0.60) | KMOKDM4E | |
| SCHEMBL3133736 | 0.75 | MAPT (0.52) | KMOMEN1POLBKMT2A | |
| SCHEMBL4900044 | 0.75 | MAP4K4 (0.54) | KMOMAP4K4KDM4EMEN1PRNP | |
| SCHEMBL31301337 | 0.75 | KMO (0.54) | KMOMAP4K4MEN1KMT2A | |
| SCHEMBL4892007 | 0.75 | MAP4K4 (0.54) | KMOMAP4K4DHODHKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820704-B2 | Substituted heteroaryl derivatives, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20050261294-A1 | Substituted heteroaryl derivatives, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261294-A1 | Substituted heteroaryl derivatives, compositions, and methods of use | MC5R, MC3R, MC4R | KMO 141/4885MAP4K4 2820/4885KIF11 4475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.